Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: An Open-Label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (Prgcd) in Patients With Gaucher's Disease Who Require Enzyme Replacement Therapy (Protalix)

 


An Open-Label Expanded Access Trial of Plant Cell Expressed Recombinant Human Glucocerebrosidase (Prgcd) in Patients With Gaucher's Disease Who Require Enzyme Replacement Therapy (Protalix)


Trial Focus

Trial Focus

Genetics/Hereditary Conditions

Objective

        
This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued due to shortage of the product.

Trial Status

Accepting Participants

Contact

Cara Wells at 720-848-6589

Eligibility and Other Participant Information


Inclusion Criteria
•Males and females, 18 years or older
•Diagnosis of Gaucher disease treated historically with imiglucerase
•Able to provide written informed consent
Exclusion Criteria
•Currently taking another experimental drug for any condition
•History of allergy to carrots
•Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions
•Allergy to beta-lactam antibiotics
•Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study.